ERBB2 and gastric cancer: In addition, the latest research found that the combination of anti-glutamine metabolic inhibitors and antiangiogenic drugs in HER2-positive gastric cancer provides a new direction for reversing the drug resistance of trastuzumab, which highlights the synergistic effect of targeted macrophage metabolism therapy and antiangiogenic therapy [142].